LETTER
Synthesis of Unsymmetrical 2,3-Diarylindoles
413
(9) (a) Ishikura, M.; Kamada, M.; Terashima, M. Synthesis
1984, 936. (b) Yang, Y.; Martin, A. R. Synth. Commun.
1992, 22, 1757. (c) Carrera, G. M. J. r.; Sheppard, G. S.
monocoupling product. This might be explained by the
strong electron-withdrawing effect of the sulfonyl group
which results in an increased reactivity of both carbon C-
2 and C-3 of the indole moiety and a less pronounced dif-
ference between their electronic character. In case of N-
methyl-2,3-dibromoindole (1) the electronic character of
C-2 and C-3 appears to be sufficiently different because
site-selective transformations are observed.
Synlett 1994, 93. (d) Tidwell, J. H.; Peat, A. J.; Buchwald,
S. L. J. Org. Chem. 1994, 59, 7164. (e) Banwell, M. G.;
Bissett, B. D.; Busato, S.; Cowden, C. J.; Hockless, D. C. R.;
Holman, J. W.; Read, R. W.; Wu, A. W. J. Chem. Soc.,
Chem. Commun. 1995, 2551. (f) Merlic, C. A.; McInnes,
D. M.; You, Y. Tetrahedron Lett. 1997, 38, 6787.
(g) Merlic, C. A.; McInnes, D. M. Tetrahedron Lett. 1997,
38, 7661. (h) Moody, C. J.; Doyle, K. J.; Elliott, M. C.;
Mowlem, T. J. J. Chem. Soc., Perkin Trans. 1 1997, 2413.
(i) Chu, L.; Fisher, M. H.; Goulet, M. T.; Wyvratt, M. J.
Tetrahedron Lett. 1997, 38, 3871. (j) Carbonnelle, A.-C.;
González-Zamora, E. G.; Beugelmans, R.; Roussi, G.
Tetrahedron Lett. 1998, 39, 4467. (k) For reactions of
triflates, see: Chi, S. M.; Choi, J.-K.; Yum, E. K.; Chi, D. Y.
Tetrahedron Lett. 2000, 41, 919. (l) Joseph, B.; Malapel, B.;
Mérour, J.-Y. Synth. Commun. 1996, 26, 3289.
In conclusion, we have reported the synthesis of symmet-
rical and unsymmetrical 2,3-diarylindoles by Suzuki–
Miyaura reactions of N-methyl-2,3-dibromoindole. The
nitrogen protective groups play an important role for the
site-selectivity.
Acknowledgment
Financial support by State of Pakistan (HEC scholarships for M.H.
and I.U.), by the DAAD (scholarships for M.F.I., A.A. and O.-U.-
R.A.), and by the State of Mecklenburg-Vorpommern (scholarship
for M.H.) is gratefully acknowledged.
(m) Malapel-Andrieu, B.; Mérour, J.-Y. Tetrahedron 1998,
54, 11079.
(10) Kawasaki, I.; Yamashita, M.; Ohta, S. Chem. Pharm. Bull.
1996, 44, 1831.
(11) Hussain, M.; Dang, T. T.; Langer, P. Synlett 2009, 1822.
(12) (a) Liu, Y.; Gribble, G. W. Tetrahedron Lett. 2000, 41,
8717. (b) For metal–halide exchange, see: Liu, Y.; Gribble,
G. W. Tetrahedron Lett. 2002, 43, 7135.
(13) General Procedure for the Synthesis of 3a–e and 4a–e
The reaction was carried out in a pressure tube. A 1,4-
dioxane solution (4 mL) of 1, K3PO4, Pd(PPh3)4, and
arylboronic acid 2 was stirred at 110 °C or 70 °C for 6 h or 8
h. After cooling to 20 °C, a sat. aq solution of NH4Cl was
added. The organic and the aqueous layer were separated,
and the latter was extracted with CH2Cl2. The combined
organic layers were dried (Na2SO4), filtered, and the filtrate
was concentrated in vacuo. The residue was purified by flash
chromatography (silica gel, heptanes).
(14) 2,3-Bis(4-ethylphenyl)-1-methyl-1H-indole (3c)
Starting with 1 (289 mg, 1.0 mmol), 2c (262 mg, 2.3 mmol),
K3PO4 (446 mg, 2.1 mmol), Pd(PPh3)4 (3 mol%), and 1,4-
dioxane (4 mL), 3c was isolated as a yellowish oil (291 mg,
86%). 1H NMR (300 MHz, CDCl3): d = 1.01 (t, J = 7.5 Hz,
3 H, CH3), 1.05 (t, J = 7.5 Hz, 3 H, CH3), 2.40 (q, J = 7.5 Hz,
2 H, CH2), 2.48 (q, J = 7.5 Hz, 2 H, CH2), 3.42 (s, 3 H,
NCH3), 6.90–6.96 (m, 3 H, ArH), 7.02–7.10 (m, 7 H, ArH),
7.25 (d, J = 8.2 Hz, 1 H, ArH), 7.51 (d, J = 7.8 Hz, 1 H,
ArH). 13C NMR (75.47 MHz, CDCl3): d = 15.8 (CH3), 16.0
(CH3), 29.1 (CH2), 29.2 (CH2), 31.2 (CH3), 110.7 (CH),
115.4 (C), 120.0 (CH), 121.0 (CH), 123.0 (CH), 128.1 (C),
128.5 (2 CH), 128.7 (2CH), 130.3 (C), 130.6 (2 CH), 132.0
(2 CH), 133.7 (C), 138.3 (C), 138.4 (C), 142.0 (C), 144.9
(C). IR (ATR): n = 3047 (w), 3022 (w), 2961 (s), 2928 (w),
1797 (w), 1765 (w), 1726 (w), 1519 (m), 1463 (s), 1362 (m),
1325 (m), 1257 (m), 1131 (w), 1115 (w), 1089 (m), 1060
(w), 1017 (m), 967 (w), 923 (w), 869 (m), 836 (s), 801 (w),
740 (s), 652 (w), 629 (m), 545 (m) cm–1. MS (EI, 70 eV):
m/z (%) = 340 (28) [M + 1]+, 339 (100) [M+], 324 (34), 309
(5), 294 (5), 281 (5), 278 (4), 146 (5). HRMS (EI): m/z calcd
for C25H25N [M+]: 339.19815; found: 339.197901.
(15) 3-Bromo-2-(3,4-dimethoxyphenyl)-1-methyl-1H-indole
(4d)
References and Notes
(1) (a) Szmuszkovicz, J.; Glenn, E. M.; Heinzelman, R. V.;
Hester, J. B. Jr.; Youngdale, G. A. J. Med. Chem. 1966, 9,
527. (b) El-Diwani, H.; Nakkady, S. S.; Hishmat, O. H.; El-
Shabrawy, O. A.; Mahmoud, S. S. Pharmazie 1992, 47, 178.
(c) El-Diwani, H. I.; Shmeiss, N. A. M. M.; Saleh, N. M. Pol.
J. Chem. 1995, 69, 470. (d) Shmeiss, N. A. M. M.; Ismail,
M. M. F.; El-Diwani, H. I.; Hassan, A. B.; Nada, S. A.
Modell., Meas. Control C 1997, 55, 11. (e) Jones, R. L.;
Qian, Y.-M.; Wise, H.; Wong, H. N. C.; Lam, W.-L.; Chan,
H.-W.; Yim, A. P. C.; Ho, J. K. S. J. Cardiovasc.
Pharmacol. 1997, 29, 525. (f) Hishmat, O. H.; Ebeid, M. Y.;
Nakkady, S. S.; Fathy, M. M.; Mahmoud, S. S. Boll. Chim.
Farm. 1999, 138, 259.
(2) (a) Glenn, E. M.; Bowman, B. J.; Kooyers, W.; Koslowske,
T.; Myers, M. L. J. Pharmacol. Exp. Ther. 1967, 155, 157.
(b) Kaiser, D. G.; Glenn, E. M.; Johnson, R. H.; Johnston,
R. L. J. Pharmacol. Exp. Ther. 1967, 155, 174.
(c) Whitehouse, M. W. J. Pharm. Pharmacol. 1967, 19,
590. (d) Collier, H. O. J.; James, G. W. L.; Piper, P. J. Br. J.
Pharmacol. 1968, 34, 76. (e) Brune, K.; Graf, P.; Glatt, M.
Agents Actions 1976, 6, 159. (f) Podos, S. M.; Becker, B.
Invest. Ophthalmol. 1976, 15, 841. (g) Spinelli, H. M.;
Krohn, D. L. Arch. Ophthalmol. 1980, 98, 1106. (h) Klug,
R. D.; Krohn, D. L.; Breitfeller, J. M.; Dieterich, D.
Ophthalmic Res. 1981, 13, 122.
(3) For a recent study, see: McAdam, B. F.; Catella-Lawson, F.;
Mardini, I. A.; Kapoor, S.; Lawson, J. A.; FitzGerald, G. A.
Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 272.
(4) For a recent review of indole syntheses, see: Gribble, G. W.
J. Chem. Soc., Perkin Trans. 1 2000, 1045.
(5) Review: Schröter, S.; Stock, C.; Bach, T. Tetrahedron 2005,
61, 2245.
(6) Dang, T. T.; Dang, T. T.; Rasool, N.; Villinger, A.; Langer,
P. Adv. Synth. Catal. 2009, 351, 1595.
(7) Dang, T. T.; Dang, T. T.; Ahmad, R.; Reinke, H.; Langer, P.
Tetrahedron Lett. 2008, 49, 1698.
Starting with 1 (289 mg, 1.0 mmol), 2i (200 mg, 1.1 mmol),
K3PO4 (318 mg, 1.5 mmol), Pd(PPh3)4 (3 mol%), and 1,4-
dioxane (4 mL), 4d was isolated as a yellowish solid (272
mg, 79%), mp 146–148 °C. 1H NMR (300 MHz, CDCl3):
d = 3.59 (s, 3 H, NCH3), 3.84 (s, 3 H, OCH3), 3.87 (s, 3 H,
OCH3), 6.93–6.95 (m, 2 H, ArH), 7.11–7.27 (m, 4 H, ArH),
(8) Dang, T. T.; Villinger, A.; Langer, P. Adv. Synth. Catal.
2008, 350, 2109.
Synlett 2010, No. 3, 411–414 © Thieme Stuttgart · New York